Computational exploration of the significance of COPS6 in cancer: Functional and clinical relevance across tumor types

Figure 5 Mutation analysis of COP9 signalosome subunit 6. A: Mutation frequency and types visualized through the cBioPortal website; B: Three-dimensional structure highlighting the R197C/H mutation site in COP9 signalosome subunit 6 (COPS6); C: Mutation sites depicted in the cBioPortal website; D: Survival analysis of COPS6 mutations in pan-cancer; E: Correlation of COPS6 with tumor mutational burden (tumor mutational burden) in pan-cancer using R software; F: Correlation of COPS6 with microsatellite instability (microsatellite instability) in pan-cancer using R software; G: Promoter methylation levels of COPS6 in prostate adenocarcinoma (PRAD), lung squamous cell carcinoma (LUSC), head and neck squamous cell carcinoma (HNSC), breast invasive carcinoma (BRCA), bladder cancer (BLCA), and kidney renal clear cell carcinoma (KIRC) accessed through the UALCAN website. OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; DSS: Disease-specific survival.